News
-
TOKYO — FUJIFILM Toyama Chemical Co., Ltd. (Head Office: Chuo-ku, Tokyo; President: Junji Okada; hereinafter “FUJIFILM Toyama Chemical”) today filed an application to the Ministry of Health, Labour and Welfare for marketing authorization approval its new radiopharmaceutical compound F-1515 (INN: lutetium [177Lu] oxodotreotide) for the treatment of pancreatic, gastrointestinal, and pulmonary neuroendocrine tumors. F-1515 is […]
-
At Fujifilm, our dedication to science and innovation has never been more important than it is today. We are collaborating across the globe and working together and finding ways to fight COVID-19 by leveraging our talents, experience and resources. But perhaps nothing is more inspiring than the way several FUJIFILM Group companies came together recently […]
-
Centus Biotherapeutics Announces Positive CHMP Opinion for FKB238, Biosimilar Bevacizumab
LONDON and TOKYO ― Centus Biotherapeutics Ltd., a joint venture between Fujifilm Kyowa Kirin Biologics Co., Ltd. and AstraZeneca PLC (LSE/STO/NYSE: AZN), today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the Marketing Authorization Application of EquidacentTM (Product Code: FKB238), the company’s biosimilar […]
-
Mylan and Fujifilm Kyowa Kirin Biologics Announce U.S. FDA Approval of Hulio® (adalimumab-fkjp)
HERTFORDSHIRE, England, PITTSBURGH and TOKYO – Mylan N.V. (NASDAQ: MYL) and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Hulio® (adalimumab-fkjp), a biosimilar to AbbVie’s Humira® (adalimumab), for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis (4 years and older), psoriatic arthritis, ankylosing spondylitis, adult […]
-
FUJIFILM Corporation (President: Kenji Sukeno) partners with Dr. Reddy’s Laboratories Ltd. (Co-Chairman & Managing Director: G. V. Prasad, hereinafter “Dr. Reddy’s”), a global pharmaceutical company headquartered in India and Global Response Aid (CEO：Mitch Wilson; hereinafter “GRA”), a global provider of medical supplies and pharmaceuticals, aimed at overseas deployment of a treatment drug for the novel […]
-
FUJIFILM Pharmaceuticals U.S.A., Inc. a wholly owned U.S. subsidiary of FUJIFILM Holdings America Corporation, has published three new technical papers highlighting animal study results of liposomes as a delivery agent to enhance anti-cancer therapeutics for solid-tumors. Each technical paper highlights preclinical study data which demonstrates increased pharmacological efficacy of liposomes coupled with anti-cancer agents. Artificially […]
-
FUJIFILM Corporation (President: Kenji Sukeno) announced that it will collaborate with Merck & Co., Inc., Kenilworth, N.J., U.S.A. (NYSE: MRK), known as MSD outside the United States and Canada. It signed a clinical collaboration agreement with MSD International GmbH, effective May 25, for the implementation of a clinical trial that evaluates a combination therapy with […]
-
Fujifilm accelerates production of its influenza antiviral drug “Avigan® Tablet” for COVID-19
FUJIFILM Corporation (President: Kenji Sukeno) has announced that it has expanded its manufacturing capacity at FUJIFILM Toyama Chemical Co., Ltd. to significantly increase production of its influenza antiviral drug “Avigan® Tablet” (generic name: favipiravir) for treating patients with COVID-19. To further boost the supply of Avigan, Fujifilm is allocating additional capacity at its FUJIFILM Wako Pure Chemical Co., Ltd. facility in Japan, for production of pharmaceutical intermediates used to manufacture Avigan. In […]
-
FUJIFILM Corporation (President: Kenji Sukeno) announces the initiation of a U.S. phase II clinical trial to evaluate the safety and efficacy of its influenza antiviral drug “Avigan® Tablet” (generic name: favipiravir) for patients with COVID-19, a respiratory infection caused by the novel SARS-CoV-2 coronavirus. Avigan, approved in Japan for manufacture and sale as an influenza antiviral drug, […]
-
FUJIFILM Corporation (President: Kenji Sukeno) announces that today it will begin to offer contract services of process development and manufacturing of liposome formulations to its partners seeking drug delivery formulations that are designed to deliver the therapeutic to the affected sites. The service will include both small molecule drugs and nucleic acid medicines*1 which are […]